<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660502</url>
  </required_header>
  <id_info>
    <org_study_id>BC3-CT017</org_study_id>
    <nct_id>NCT02660502</nct_id>
  </id_info>
  <brief_title>An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects</brief_title>
  <official_title>A Double-blind, Comparator-controlled, Randomised, Three-period Crossover Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adocia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adocia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomised, three period crossover phase 1 trial using automated
      8-hour euglycemic clamps in healthy Japanese subjects.

      Each subject will be randomly allocated to one out of nine sequences to receive either three
      single doses of BioChaperone insulin lispro or one single dose of Humalog® and two single
      doses of BioChaperone insulin lispro on three separate dosing visits.

      The total trial maximum duration for a subject will be up to 10 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCLispro(0-30min)</measure>
    <time_frame>Up to 30 minutes</time_frame>
    <description>Area under the insulin lispro serum concentration - time curve from t=0 to 30 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCGIR(0-last)</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Area under the glucose infusion rate time curve from 0 hours until the end of clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 10 weeks</time_frame>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.1 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.2 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BioChaperone insulin lispro 0.4 U/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Humalog®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biochaperone insulin lispro 0.1 U/kg</intervention_name>
    <description>Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg</description>
    <arm_group_label>BioChaperone insulin lispro 0.1 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biochaperone insulin lispro 0.2 U/kg</intervention_name>
    <description>Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg</description>
    <arm_group_label>BioChaperone insulin lispro 0.2 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Biochaperone insulin lispro 0.4 U/kg</intervention_name>
    <description>Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg</description>
    <arm_group_label>BioChaperone insulin lispro 0.4 U/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humalog®</intervention_name>
    <description>Injection of a single dose of Humalog® at the dose of 0.2 U/kg</description>
    <arm_group_label>Humalog®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese male or female subjects by completion of medical history, physical
             examination and biochemical investigations as judged by the Investigator.

          -  BMI between 18.5 and 25.0 kg∙m-2, both inclusive.

          -  Fasting Plasma Glucose ≤ 5.6 mmol/L (100 mg/dL).

          -  Signed and dated informed consent obtained before any trial-related activities.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to trial product(s) or related products.

          -  Receipt of any investigational medicinal product within 3 months before randomisation
             in this trial.

          -  Any history or presence of a life threatening disease (i.e. cancer except basal cell
             skin cancer or squamous cell skin cancer), or of clinically relevant cardiovascular,
             pulmonary, gastrointestinal, hepatic, renal, metabolic (including type 1 and type 2
             diabetes mellitus, haematological, neurological, osteomuscular, articular,
             psychiatric, systemic, ocular, gynaecologic (if female), or infectious disease, or
             signs of acute illness as judged by the investigator.

          -  History of multiple and/or severe allergies to drugs or foods or a history of severe
             anaphylactic reaction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Andersen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

